Binding of sulphonylureas to plasma proteins – A KATP channel perspective
Open Access
- 17 May 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (5) , e0197634
Abstract
Sulphonylurea drugs stimulate insulin secretion from pancreatic β-cells primarily by inhibiting ATP sensitive potassium (KATP) channels in the β-cell membrane. The effective sulphonylurea concentration at its site of action is significantly attenuated by binding to serum albumin, which makes it difficult to compare in vitro and in vivo data. We therefore measured the ability of gliclazide and glibenclamide to inhibit KATP channels and stimulate insulin secretion in the presence of serum albumin. We used this data, together with estimates of free drug concentrations from binding studies, to predict the extent of sulphonylurea inhibition of KATP channels at therapeutic concentrations in vivo. KATP currents from mouse pancreatic β-cells and Xenopus oocytes were measured using the patch-clamp technique. Gliclazide and glibenclamide binding to human plasma were determined in spiked plasma samples using an ultrafiltration-mass spectrometry approach. Bovine serum albumin (60g/l) produced a mild, non-significant reduction of gliclazide block of KATP currents in pancreatic β-cells and Xenopus oocytes. In contrast, glibenclamide inhibition of recombinant KATP channels was dramatically suppressed by albumin (predicted free drug concentration ATP channels and stimulate insulin secretion.Keywords
Funding Information
- Wellcome (884655)
- Wellcome (089795)
- European Commission (322620)
This publication has 51 references indexed in Scilit:
- Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabeticsAmerican Journal of Physiology-Endocrinology and Metabolism, 2012
- GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: Implications for understanding genetic association signals at this locusMolecular Genetics and Metabolism, 2011
- Variations in tissue selectivity amongst insulin secretagogues: a systematic reviewDiabetes, Obesity and Metabolism, 2011
- High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albuminAnalytical and Bioanalytical Chemistry, 2011
- Activation of the KATP channel by Mg-nucleotide interaction with SUR1Journal of General Physiology, 2010
- Incomplete dissociation of glibenclamide from wild‐type and mutant pancreatic KATPchannels limits their recovery from inhibitionBritish Journal of Pharmacology, 2009
- Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic β cells recapitulates neonatal diabetesJournal of Clinical Investigation, 2008
- Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 MutationsNew England Journal of Medicine, 2006
- Influence of blood proteins on biomedical analysis. IX Protective effects of human serum proteins on anion-induced degradation of gliclazide.Chemical and Pharmaceutical Bulletin, 1986
- Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamideDiabetologia, 1980